Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Climbing Mount Everest: An Individual Victory - 2Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- 3Bomb blast in packed Nigerian mosque kills five
- 4Deadly heat worldwide prompts $300 million for climate health research at COP30
- 5Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- Fundamental Home Machines: An Easy to understand Determination Guide
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Exploring Programming Greatness: A Survey of \Easy to use Connection points\
- 10 High priority Contraptions for Tech Aficionados
- Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- Vote in favor of Your #1 BWM Vehicles
- 4 astronauts are en route home from ISS after medical issue forces early exit
